1715 38TH ST, BOULDER, CO
Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Financial Results, Press Release
News
Q1
FY 2024
Q3
Q2
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Additional Securities
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership